KPE-C-046 KPE’s Certificate Course in Drug Regulatory Affairs
Posted on08 Jan 2018
Comments0
Course Content / Learning Schedules
+91-98 455 710 46 | info@nckpharma.com
Sign In
|Sign Up
Please sign in first
Not a member?
Please simply create an account before buying/booking any courses.
Create an account for free!
- Home
- About Us
- NCK services
- Course List
- Admission
- Course Quick Glance
- Features of Online Courses
- Course Catalogue
- Course Application form
- Admission Notification & Special Offers
- Frequently asked question related to KPE courses
- Prospect Identification Process
- Final Examination Registration
- How to change / reset password?
- Course Upgrade
- Verify Course Certificate
- Request for Course Completion Certificate
- Knowledge Base
- Contact
KPE-C-103 Executive Program in Global Drug Regulatory Affairs [EPGDRA]
Our Popular Courses
Recent Articles
- Pfizer to acquire Biohaven Pharma for $11.6 billion
- EMA recommendation for 2022-2023 seasonal flu vaccine composition
- Aurobindo Pharma acquires Veritaz Healthcare
- Sun Pharma to launch Vortioxetine in India
- what is meaning of clinically significant endpoint?
- US FDA grants Breakthrough Therapy Designation for Pfizer’s RSVpreF
- Is HEOR and Market Access is same?
- Symbicort 1st generic Approval by USFDA
- Case Study : Vimpat patent expired on 17th of March, 2022 and generic entry
- Case Study : US FDA approval of Marinus Pharma’s Ztalmy
- Lynk Pharma, Simcere licensing deal for development of novel JAK1 inhibitor LNK01001 in China
- What if Design of experiments (DoE) approach?
- Torrent Pharma to manufacture and sell Pfizer’s Paxlovid generic
- What are the application of IVIVC?
- What is the meaning of IVIVC?
- Insight on AstraZeneca’s global R&D Postdoctoral Challenge initiative
- Medtronic launched MiniMed 780G system to manage type 1 diabetes
- Case Study: Pfizer’s Arena acquisition – A $6.7B deal
- Market Access – Check your competency
- Zydus gets orphan drug designation from USFDA for antimalarial compound